Grifois (GRFS) Stock: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$7.46
0.05 (0.67%)
â˛
5d:
+2.05%
30d:
-2.48%
90d:
+3.61%
WAIT
LOW Confidence
Analysis Updated: Oct 9, 2026 12:00 AM ET
Earnings: Sep 28, 2026
0d
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GRFS is fairly priced but lacks strong directional signals. At -3.7% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GRFS is fairly priced but lacks strong directional signals. At -3.7% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.06
Based on 14.2% avg growth
INTRINSIC VALUE TODAY
$9.97
25.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $7.46, which is considered fair relative to its 30-day fair value range of $7.27 to $7.64. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.2) compared to its historical average (5.8). Remarkably, the market is currently pricing in an annual earnings decline of 3.7% over the next few years. This pessimistic expectation contrasts with the company's recent 32.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is showing sideways momentum. The price is approaching resistance at $7.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.87 (+45.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GRFS is showing sideways momentum. The price is approaching resistance at $7.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.87 (+45.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.27 -
$7.64
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.6% below Wall St target ($10.87)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.27 -
$7.64
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.20
Resistance Level
$7.57
Current Trend
Sideways
Technical data as of
Oct 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.17
Wall Street Target
$10.87
(+45.6%)
Revenue Growth (YoY)
-0.9%
Earnings Growth (YoY)
32.9%
Profit Margin
6.1%
Valuation Discount vs History
-3.7% cheaper
PE vs Historical
5.2 vs 5.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.7%
(market-implied from PE analysis)
1-Year Target
$7.18
(-4%)
2-Year Target
$6.92
(-7%)
3-Year Target
$6.66
(-11%)
3-Yr Target (if PE normalizes)
(PE: 5â6)
$7.47
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 24.3%)
$55.00
(+637%)
Base:
(SPY PE: 5.2, Growth: 24.3%)
$14.32
(+92%)
Bear:
(PE: 4.4, Growth: 24.3%)
$12.17
(+63%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (10x PE), but valuation improves significantly next year (5x PE) as earnings recover.
Trailing PE: 9.62 | Current EPS (TTM): $0.77
Bull Case
$15.27
(+105%)
Analyst growth 87.3%, PE expands to 10.6
Base Case
$13.88
(+86%)
Market implied 87.3%, PE stable at 9.6
Bear Case
$5.04
(-33%)
Severe decline -20.0%, PE contracts to 8.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.2 to 5.8
Stabilization Target:
$8.37
(+12.2%)
PE Expansion Potential:
+12.2%
Share & Embed Analysis
Last updated: October 12, 2026 3:12 AM ET
Data refreshes hourly during market hours. Next update: 4:12 AM
Data refreshes hourly during market hours. Next update: 4:12 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
30 analysts |
$1330 | 54 HOLD |
|
ABBV
AbbVie Inc |
STRONG BUY
30 analysts |
$281 | 54 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$159 | 51 HOLD |
|
BIIB
Biogen Inc |
BUY
35 analysts |
$239 | 55 HOLD |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$158 | 57 HOLD |
